Edinburgh-based biotech startup Concinnity Genetics has efficiently closed an oversubscribed €3.6 million seed funding spherical.
The funding was led by Eos Advisory, with participation from Scottish Enterprise, Previous Faculty Capital—the College of Edinburgh’s enterprise funding fund—and Maven Capital Companions.
This funding may even allow Concinnity to spin out from the lab of Professor Susan Rosser and the UKRI UK Centre for Mammalian Artificial Biology on the College of Edinburgh and set up operations in Scotland’s life science hub.
“We’re so excited to be taking the following step in our spin-out journey and need to sincerely thank all of the buyers and supporters who’ve helped us make it occur. Our ambition is to be the go-to accomplice for gene management to make gene and cell therapies as protected as attainable,” mentioned CEO Jessica Birt. “This dedication from our buyers, constructing on the continuing assist from Scottish Enterprise, speaks to the potential they see in our work, and we stay up for utilizing the funding to additional develop our expertise.”
Co-founded in 2023 by CEO Jessica Birt and CSO Dr Matthew Dale, Concinnity Genetics is a spinout from the College of Edinburgh. The corporate focuses on growing novel management mechanisms that permit exact regulation of gene therapies even after administration.
By integrating artificial biology with AI, their expertise allows gene therapies to regulate dynamically, probably decreasing uncomfortable side effects and enhancing therapeutic outcomes.
The funds are earmarked to provoke three new programmes growing ribonucleic acid (RNA)-based management techniques focused at key purposes throughout the cell and gene remedy market, in addition to persevering with to develop Concinnity’s present management techniques with the goal of acquiring crucial knowledge to provoke partnerships with clients.
Andrew McNeill, Managing Associate at Eos Advisory, commented: “Concinnity is an ideal match for Eos’s deal with backing pioneering Scottish science, addressing a major unmet want in gene remedy. By combining artificial biology and AI-machine studying, the Concinnity expertise has been described because the ‘holy grail for rising gene therapies’, making such remedies each simpler and safer.”
Over the previous two years, Concinnity has been supported by Scottish Enterprise as a part of its Excessive Progress Spinout Programme. This funding has enabled the group to develop its expertise, producing knowledge for business validation that has supported the profitable completion of this seed funding.
“This funding spherical clearly demonstrates the massive potential of Concinnity’s expertise, which has been recognised by buyers. Scottish Enterprise has supported the group since its beginnings throughout the College of Edinburgh, so it’s incredible to now be investing in it because it prepares to spin out,” mentioned Kerry Sharp, Director of Entrepreneurship and Funding at Scottish Enterprise. “Life sciences is one among Scotland’s key development industries and our funding and ongoing enterprise assist will assist Concinnity convert and scale its innovation into worldwide development, delivering most advantages for Scotland’s financial system.”
Concinnity Genetics represents an development within the area of gene remedy, with its AI-driven RNA management techniques probably setting new requirements in therapy security and efficacy.